公开(公告)号：WO1994003170A1

公开(公告)日：1994-02-17

申请号：PCT/US1993007260

申请日：1993-08-03

Applicant: SEPRACOR INC. ,  GEORGETOWN UNIVERSITY

Inventor： SEPRACOR INC. ,  GEORGETOWN UNIVERSITY ,  YOUNG, James, W. ,  GRAY, Nancy, M. ,  WOOSLEY, Raymond, L. ,  CHEN, Yiwang

IPC: A61K31/445

CPC classification number: A61K45/06 ,  A61K31/445 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising a compound of formula (I): wherein Z is COOH, COOCH3 or CH2OH, or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of a compound of formula (I) to a human patient.

Abstract translation: 一种药物组合物，其包含式（I）化合物：其中Z为COOH，COOCH 3或CH 2 OH或其药学上可接受的盐，用于不引起任何明显心律不齐的抗组胺治疗，包括给予治疗有效的 式（I）化合物与人类患者的量。

公开(公告)号：WO1994007495A1

公开(公告)日：1994-04-14

申请号：PCT/US1993008349

申请日：1993-09-03

Applicant: SEPRACOR INC. ,  GEORGETOWN UNIVERSITY

Inventor： SEPRACOR INC. ,  GEORGETOWN UNIVERSITY ,  WOOSLEY, Raymond, L. ,  ABERG, A., K., Gunnar

IPC: A61K31/445

CPC classification number: A61K31/445 ,  A61K31/454 ,  A61K2300/00 ,  A61K31/00

Abstract: A pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in an anti-histaminic treatment which does not induce any significant cardiac arrhythmia, comprising administering a therapeutically effective amount of the compound of formula (I) to a human patient.

Abstract translation: 一种药物组合物，其包含式（I）化合物或其药学上可接受的盐，用于不诱导任何明显心律不齐的抗组胺治疗，包括给予治疗有效量的式（I）化合物至 一个人的病人。

公开(公告)号：WO1997045113A1

公开(公告)日：1997-12-04

申请号：PCT/US1997007568

申请日：1997-05-05

Applicant: SEPRACOR INC.

Inventor： SEPRACOR INC. ,  JOCHLE, Wolfgang

IPC: A61K31/19

CPC classification number: A61K31/192 ,  A23K20/111 ,  A61K45/06

Abstract: Compositions and methods for regulating the reproductive cycle of domesticated animals using nonsteroidal anti-inflammatory drugs (NSAIDs). Further, the present invention relates to compositions and methods for controlling and managing the breeding of domesticated animals, especially pigs, by synchronizing their reproductive cycles by administering an effective amount of an NSAID compound, preferably ketoprofen. Optionally, one or several additional active ingredients such as a hormone or steroid may be administered in conjunction with the NSAID compound in order to synchronize the reproductive cycle, especially estrus and/or ovulations.

Abstract translation: 使用非甾体抗炎药（NSAIDs）调节驯养动物繁殖周期的组合物和方法。 此外，本发明涉及通过施用有效量的NSAID化合物，优选酮洛芬来同步其生殖周期来控制和管理驯养动物，特别是猪的育种的组合物和方法。 任选地，一种或多种另外的活性成分例如激素或类固醇可以与NSAID化合物一起施用，以使生殖周期，特别是发情和/或排卵同步。

公开(公告)号：WO1996013226A1

公开(公告)日：1996-05-09

申请号：PCT/US1995013989

申请日：1995-10-30

Applicant: SEPRACOR INC. ,  ABERG, A., K., Gunnar

Inventor： SEPRACOR INC.

IPC: A61F02/00

CPC classification number: A61K45/06 ,  A61K31/167 ,  A61K31/60 ,  A61K38/1841 ,  A61K38/1866 ,  A61K38/30 ,  A61K2300/00

Abstract: A method for the treatment of periodontitis and a pharmaceutical composition for use in the method. According to a preferred embodiment, the method comprises administering to a mammal afflicted with periodontitis a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide growth factor and an NSAID to regenerate dental tissue in the mammal afflicted with periodontitis and, thereafter, administering to the mammal a therapeutically effective amount of an NSAID to prevent resorption of the newly regenerated dental tissue.

Abstract translation: 治疗牙周炎的方法和用于该方法的药物组合物。 根据优选的实施方案，所述方法包括向患有牙周炎的哺乳动物施用治疗有效量的包含多肽生长因子和NSAID的药物组合物，以再生患有牙周炎的哺乳动物中的牙齿组织，然后施用于哺乳动物 治疗有效量的NSAID以防止新再生的牙科组织的再吸收。

公开(公告)号：WO1994001112A1

公开(公告)日：1994-01-20

申请号：PCT/US1993006379

申请日：1993-07-06

Applicant: SEPRACOR INC.

Inventor： SEPRACOR INC. ,  GRAY, Nancy, M. ,  YOUNG, James, W.

IPC: A61K31/445

CPC classification number: A61K31/445 ,  A61K31/4468

Abstract: Methods are disclosed utilizing the optically pure (-) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cisapride. This compound is also useful in treating or preventing emesis while avoiding the adverse effects associated with racemic cisapride. The optically pure (-) isomer of cisapride is also useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (-) cisapride as a prokinetic agent such as gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (-) isomer of cisapride has been found to exhibit higher bioavailability over the racemic cisapride.

Abstract translation: 公开利用西沙必利的光学纯（ - ）异构体的方法。 该化合物是用于治疗胃食管反流疾病的有效药物，同时避免与西沙必利的外消旋混合物相关的副作用的伴随的责任。 该化合物也可用于治疗或预防呕吐，同时避免与外消旋西沙必利有关的不良反应。 西沙必利的旋光纯（ - ）异构体也可用于治疗消化不良和其他可能与（ - ）西沙必利作为促动力药物如胃轻瘫，便秘，手术后肠梗阻和肠道活动相关的其他病症 假性梗阻与西沙必利的外消旋混合物相关的副作用没有伴随的责任。 已经发现西沙必利的（ - ）异构体比外消旋西沙必利具有更高的生物利用度。

公开(公告)号：WO1994000047A1

公开(公告)日：1994-01-06

申请号：PCT/US1993005967

申请日：1993-06-22

Applicant: SEPRACOR INC.

Inventor： SEPRACOR INC. ,  YOUNG, James, W.

IPC: A51K31/145

CPC classification number: A61K31/135

Abstract: Methods and compositions are disclosed utilizing the optically pure (+) isomer of sibutramine, which is a potent drug for treatment of depression, Parkinson's disease, cerebral function disorders, obesity, dementia and related disorders, as well as other conditions related to the activity of the compound as an inhibitor of the neuronal reuptake of monoamines. Further, methods and compositions are disclosed utilizing optically pure (+) sibutramine in order to avoid the adverse effects associated with the administration of racemic sibutramine.

Abstract translation: 公开了使用西布曲明的光学纯（+）异构体的方法和组合物，西布曲明是用于治疗抑郁症，帕金森病，脑功能障碍，肥胖，痴呆和相关疾病的有效药物，以及与 该化合物作为单胺神经元再摄取的抑制剂。 此外，利用光学纯（+）西布曲明公开了方法和组合物，以避免与外消旋西布曲明的给药相关的不利影响。

公开(公告)号：WO1993020809A1

公开(公告)日：1993-10-28

申请号：PCT/US1993003041

申请日：1993-03-31

Applicant: SEPRACOR INC.

Inventor： SEPRACOR INC. ,  BARBERICH, Timothy, J. ,  YOUNG, James, W.

IPC: A61K31/19

CPC classification number: A61K31/405 ,  A61K31/19 ,  A61K31/38 ,  A61K31/40 ,  A61K31/557 ,  A61K2300/00

Abstract: The adverse side effects associated with the administration of arylalkanoic acid derivative drugs such as the arylpropionic acid derivatives ibuprofen, ketoprofen, or flurbiprofen are reduced by administering the S enantiomer of these drugs. In particular, the adverse side effects of gastrointestinal toxicity or irritation and of kidney toxicity are reduced. The S enantiomer drug compositions are also disclosed.

Abstract translation: 通过施用这些药物的S对映异构体，减少与芳基链烷酸衍生物药物如芳基丙酸衍生物布洛芬，酮洛芬或氟比洛芬的给药有关的副作用。 特别是，胃肠道毒性或刺激和肾脏毒性的不良副作用降低。 还公开了S对映异构体药物组合物。

公开(公告)号：WO1996040133A1

公开(公告)日：1996-12-19

申请号：PCT/US1996007159

申请日：1996-05-17

Applicant: SEPRACOR INC.

Inventor： SEPRACOR INC. ,  MCCULLOUGH, John, R. ,  ABERG, A., K., Gunnar

IPC: A61K31/445

CPC classification number: A61K31/496 ,  A61K31/44 ,  A61K31/445 ,  A61K31/4468 ,  A61K31/495 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods are disclosed utilizing the optically pure (-) isomer of norcisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease, emesis, dispepsia and other conditions while substantially reducing the concomitant liability of adverse effects associated with cisapride. The (-) isomer of norcisapride also avoids the adverse drug interactions associated with racemic cisapride and other therapeutic agents.

Abstract translation: 公开利用诺西西滨的旋光纯（ - ）异构体的方法。 该化合物是治疗胃食管反流病，呕吐，消化不良和其他病症的有效药物，同时显着减少与西沙必利相关的副作用的伴随责任。 诺西沙必利的（ - ）异构体也避免与外消旋西沙必利和其他治疗剂相关的不良药物相互作用。

公开(公告)号：WO1995028152A1

公开(公告)日：1995-10-26

申请号：PCT/US1995004508

申请日：1995-04-10

Applicant: SEPRACOR INC.

Inventor： SEPRACOR INC. ,  YOUNG, James, W. ,  BARBERICH, Timothy, J.

IPC: A61K31/135

CPC classification number: A61K31/135

Abstract: Methods and compositions are disclosed utilizing the pure S(+) isomer of fluoxetine which is a potent antidepressant and appetite suppressant substantially free of unwanted, adverse toxic or psychological effects. In addition, methods and compositions are disclosed utilizing the pure S(+) isomer of fluoxetine which is useful in treating migraine headaches, pain, in particular chronic pain, obsessive-compulsive disorders, sexual dysfunction and memory disorders. Further, methods and compositions for treating a condition alleviated or improved by inhibition of serotonin uptake in serotonergic neurons and platelets in a human using optically pure S(+) fluoxetine are disclosed.

Abstract translation: 公开了使用氟西汀的纯S（+）异构体的方法和组合物，其是有效的抗抑郁药和食欲抑制剂，其基本上不含有害的，不利的毒性或心理作用。 此外，公开了使用氟西汀的纯S（+）异构体的方法和组合物，其可用于治疗偏头痛，疼痛，特别是慢性疼痛，强迫症，性功能障碍和记忆障碍。 此外，公开了通过使用光学纯的S（+）氟西汀在人体中抑制5-羟色胺能神经元和血小板中5-羟色胺摄取而缓解或改善的病症的方法和组合物。

公开(公告)号：WO1994000114A1

公开(公告)日：1994-01-06

申请号：PCT/US1993005966

申请日：1993-06-22

Applicant: SEPRACOR INC.

Inventor： SEPRACOR INC. ,  YOUNG, James, W.

IPC: A61K31/135

CPC classification number: A61K31/135

Abstract: Methods and compositions are disclosed utilizing the optically pure (-) isomer of sibutramine, which is a potent drug for treatment of depression, Parkinson's disease, cerebral function disorders, obesity, dementia and related disorders, as well as other conditions related to the activity of the compound as an inhibitor of the neuronal reuptake of monoamines. Further, methods and compositions are disclosed utilizing optically pure (-) sibutramine in order to avoid the adverse effects associated with the administration of racemic sibutramine.

Abstract translation: 公开了使用西布曲明的光学纯（ - ）异构体的方法和组合物，其是用于治疗抑郁症，帕金森病，脑功能障碍，肥胖症，痴呆和相关病症的有效药物，以及与 该化合物作为单胺神经元再摄取的抑制剂。 此外，利用旋光纯（ - ）西布曲明来公开方法和组合物，以避免与施用外消旋西布曲明有关的不利影响。